DK2958573T3 - Farmaceutiske formuleringer af nitrit og anvendelser deraf - Google Patents
Farmaceutiske formuleringer af nitrit og anvendelser deraf Download PDFInfo
- Publication number
- DK2958573T3 DK2958573T3 DK14754330.0T DK14754330T DK2958573T3 DK 2958573 T3 DK2958573 T3 DK 2958573T3 DK 14754330 T DK14754330 T DK 14754330T DK 2958573 T3 DK2958573 T3 DK 2958573T3
- Authority
- DK
- Denmark
- Prior art keywords
- nitrites
- applications
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767017P | 2013-02-20 | 2013-02-20 | |
| PCT/US2014/017432 WO2014130691A2 (en) | 2013-02-20 | 2014-02-20 | Pharmaceutical formulations of nitrite and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2958573T3 true DK2958573T3 (da) | 2019-08-05 |
Family
ID=51391970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14754330.0T DK2958573T3 (da) | 2013-02-20 | 2014-02-20 | Farmaceutiske formuleringer af nitrit og anvendelser deraf |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9561249B2 (enExample) |
| EP (1) | EP2958573B1 (enExample) |
| JP (1) | JP2016509030A (enExample) |
| KR (1) | KR102472588B1 (enExample) |
| CN (1) | CN105358160A (enExample) |
| AU (1) | AU2014218916A1 (enExample) |
| BR (1) | BR112015019802A2 (enExample) |
| CA (1) | CA2899602C (enExample) |
| DK (1) | DK2958573T3 (enExample) |
| ES (1) | ES2741146T3 (enExample) |
| HK (1) | HK1218079A1 (enExample) |
| WO (1) | WO2014130691A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009065142A2 (en) * | 2007-11-15 | 2009-05-22 | Biomedical Research Foundation Of Northwest Louisiana | Use of nitrite salts in chronic ischemia |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| GB201602959D0 (en) | 2016-02-19 | 2016-04-06 | Isis Innovation | Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury |
| WO2017214157A1 (en) | 2016-06-06 | 2017-12-14 | Theravasc Inc. | Pharmaceutical formulations of nitrite uses thereof |
| JP7179299B2 (ja) * | 2017-07-14 | 2022-11-29 | 国立大学法人大阪大学 | スパースモデリングを利用した痛みの分類および瞬間痛の判別 |
| CN108785106B (zh) * | 2018-06-05 | 2021-03-16 | 中国科学院上海硅酸盐研究所 | 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用 |
| WO2020141546A1 (en) | 2019-01-02 | 2020-07-09 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for pain management |
| KR20220106982A (ko) * | 2019-10-28 | 2022-08-01 | 아카디아 파마슈티칼스 인코포레이티드 | 레트 증후군의 치료 방법 및 조성물 |
| US20260130878A1 (en) * | 2024-11-12 | 2026-05-14 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650484A (en) | 1983-02-03 | 1987-03-17 | Alza Corporation | Method for treating ischemic conditions |
| IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| US5122384A (en) | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
| US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| US20110196039A9 (en) | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
| US5692500A (en) * | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
| US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
| US7015876B1 (en) | 1998-06-03 | 2006-03-21 | Lear Corporation | Heads-up display with improved contrast |
| WO2000003725A1 (en) | 1998-07-14 | 2000-01-27 | Paracelsian, Inc. | Method for identifying and confirming consistent bio-functionality of natural compositions |
| JP2002535353A (ja) | 1999-01-29 | 2002-10-22 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | 医薬品組成物 |
| GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
| GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| JP2005524676A (ja) * | 2002-03-20 | 2005-08-18 | ザ・ユニバーシティ・オブ・クイーンズランド | 一酸化窒素供与体及びオピオイド鎮痛薬を含む方法及び組成物 |
| CA2379211A1 (fr) | 2002-03-28 | 2003-09-28 | Institut De Cardiologie De Montreal | Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase) |
| WO2005004884A2 (en) | 2003-07-09 | 2005-01-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| JP2007502831A (ja) | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| WO2005023189A2 (en) * | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
| US7362274B1 (en) | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US20060083824A1 (en) | 2004-10-20 | 2006-04-20 | Pbm Products Llc | Nutritional supplements for glucose intolerant individuals |
| CA2608651A1 (en) | 2005-05-24 | 2006-11-30 | Wellgen, Inc. | Compositions and methods for the prevention and treatment of conditions associated with inflammation |
| GB0607402D0 (en) | 2006-04-12 | 2006-05-24 | Barts & London Nhs Trust | Therapeutic composition and use |
| WO2007149520A2 (en) | 2006-06-21 | 2007-12-27 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
| KR20100014853A (ko) | 2007-02-26 | 2010-02-11 | 존 런드버그 | 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물 |
| CA2678093C (en) | 2007-02-26 | 2017-10-24 | Jon Lundberg | Performance enhancing composition and use thereof |
| WO2008153762A2 (en) | 2007-05-25 | 2008-12-18 | N30 Pharmaceuticals, Llc | S-nitrosothiol formulations and storage systems |
| WO2009065142A2 (en) | 2007-11-15 | 2009-05-22 | Biomedical Research Foundation Of Northwest Louisiana | Use of nitrite salts in chronic ischemia |
| US20090196930A1 (en) | 2007-12-27 | 2009-08-06 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
| WO2010036236A1 (en) | 2008-09-23 | 2010-04-01 | Baker Hughes Incorporated | Anchor assembly |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| WO2010147742A2 (en) * | 2009-06-18 | 2010-12-23 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
| US20130209584A1 (en) | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| CN107260756A (zh) * | 2009-10-14 | 2017-10-20 | 瑟阿瓦斯克有限公司 | 亚硝酸盐/酯的药物制剂以及其应用 |
| PT2533773E (pt) * | 2010-10-21 | 2015-12-01 | Kipax Ab | Dispositivo de administração de óxido nítrico por via cutânea tópica |
| WO2012135623A1 (en) | 2011-03-31 | 2012-10-04 | Theravasc Inc. | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline |
| US20140112983A1 (en) | 2011-04-14 | 2014-04-24 | Theravasc Inc. | Nitrite compositions and uses thereof |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
-
2014
- 2014-02-20 CN CN201480022166.1A patent/CN105358160A/zh active Pending
- 2014-02-20 JP JP2015558225A patent/JP2016509030A/ja active Pending
- 2014-02-20 CA CA2899602A patent/CA2899602C/en active Active
- 2014-02-20 ES ES14754330T patent/ES2741146T3/es active Active
- 2014-02-20 KR KR1020157025763A patent/KR102472588B1/ko active Active
- 2014-02-20 WO PCT/US2014/017432 patent/WO2014130691A2/en not_active Ceased
- 2014-02-20 DK DK14754330.0T patent/DK2958573T3/da active
- 2014-02-20 EP EP14754330.0A patent/EP2958573B1/en active Active
- 2014-02-20 AU AU2014218916A patent/AU2014218916A1/en not_active Abandoned
- 2014-02-20 BR BR112015019802A patent/BR112015019802A2/pt not_active IP Right Cessation
- 2014-02-20 HK HK16106249.8A patent/HK1218079A1/zh unknown
-
2015
- 2015-02-19 US US14/626,571 patent/US9561249B2/en active Active
-
2017
- 2017-01-05 US US15/399,208 patent/US20170143759A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218079A1 (zh) | 2017-02-03 |
| US9561249B2 (en) | 2017-02-07 |
| CA2899602A1 (en) | 2014-08-28 |
| US20170143759A1 (en) | 2017-05-25 |
| KR102472588B1 (ko) | 2022-12-01 |
| JP2016509030A (ja) | 2016-03-24 |
| AU2014218916A1 (en) | 2015-09-03 |
| BR112015019802A2 (pt) | 2017-07-18 |
| EP2958573B1 (en) | 2019-05-08 |
| EP2958573A4 (en) | 2016-10-19 |
| EP2958573A2 (en) | 2015-12-30 |
| KR20150120479A (ko) | 2015-10-27 |
| ES2741146T3 (es) | 2020-02-10 |
| CA2899602C (en) | 2024-01-30 |
| CN105358160A (zh) | 2016-02-24 |
| WO2014130691A2 (en) | 2014-08-28 |
| WO2014130691A3 (en) | 2014-10-16 |
| US20150196588A1 (en) | 2015-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3370770T3 (da) | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
| DK2968221T3 (da) | Farmaceutisk sammensætning af s-ketaminhydrochlorid | |
| HUE057734T2 (hu) | Heterociklusos vegyületek és alkalmazásuk | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK2963056T3 (da) | Insulinanalog og anvendelse deraf | |
| HUE040323T2 (hu) | PRMT5-inhibitorok és alkalmazásaik | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| HUE036672T2 (hu) | Pirazol-amid vegyület és gyógyászati alkalmazásai | |
| DK2968173T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
| DK2981541T3 (da) | Syntese og anvendelse af isotopmærkede glycaner | |
| DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
| DK2988756T4 (da) | Formulering af kontraststof og dertil knyttet fremstillingsfremgangsmåde | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK3083789T3 (da) | Overfladebehandling af partikler og anvendelse heraf | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3292873T3 (da) | Kombination af vaccination og hæmning af PD-1-vejen | |
| EP2983661C0 (en) | OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS | |
| DK3205683T3 (da) | Sammensætninger og indretninger af poly-4-hydroxybutyrat |